Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06390878
Other study ID # R24023
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 1, 2024
Est. completion date August 30, 2027

Study information

Verified date April 2024
Source Natural Resources Institute Finland
Contact Sanna Hurtola
Phone +358295322500
Email sanna.hurtola@luke.fi
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Biodiversity is essential for nature and human well-being. Land use has reduced biodiversity in cities that is associated with altered commensal microbiota and a rising burden of immunological disorders among urban children. The investigators will estimate how rewilding of kindergarten yards affects commensal microbiome, prevalence of allergies, asthma, atopic dermatitis and infections, cortisol levels, cognitive skills and plasma cytokine levels of children. Our specific aims are: To assess if rewilding diversifies health-associated skin, saliva and gut microbiota and reduces infectious diseases and atopic or allergic symptoms. Assess whether the rewilding has positive effects on cognitive skills. Assess whether the rewilding changes cortisol and plasma cytokine levels. The investigators will recruit altogether 320 (160 per treatment) study subjects aged between 1-5 to questionnaire study (Task 2), from which 120 study subjects will be analyzed more detailed using microbiological and blood samples (Task 1).


Recruitment information / eligibility

Status Recruiting
Enrollment 320
Est. completion date August 30, 2027
Est. primary completion date August 30, 2027
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 1 Year to 5 Years
Eligibility Inclusion Criteria: - Attendance in kindergarten Exclusion Criteria: - Use of antibiotics in the year before sampling

Study Design


Intervention

Biological:
Biodiversity
In rewilding kindergartens, the yards are modified with biological elements, i.e., vegetation and plantation will be added to the yards.
Other:
Playground equipment
Playground equipment that increase the physical activity of children will be added to the kindergarten yards.

Locations

Country Name City State
Finland Natural Resources Institute Finland Helsinki Uusimaa
Finland Tampere University Tampere

Sponsors (2)

Lead Sponsor Collaborator
Natural Resources Institute Finland Tampere University

Country where clinical trial is conducted

Finland, 

Outcome

Type Measure Description Time frame Safety issue
Other Associations between environmental factors and primary and secondary outcomes. Associations between environmental factors (vegetation, deadwood, and polypore richness, land cover categories and other yard characteristics) and cytokine levels, microbial measurements, white blood cell transcriptome and distribution, cortisol levels, cognitive skills, the prevalence of infectious diseases and atopy, allergy and asthma symptoms. Baseline, 3 month, 1 year, 2 year, 3 year
Primary Skin Gammaproteobacteria Difference on skin gammaproteobacterial diversity between rewilding and control group Baseline, 3 month, 1 year, 2 year, 3 year
Secondary Cortisol levels Cortisol levels measured from hair samples Baseline, 3 month, 1 year, 2 year, 3 year
Secondary Difference in diversity of skin, saliva and stool microbiota It will be analyzed if microbial communities are different between treatments Baseline, 3 month, 1 year, 2 year, 3 year
Secondary Difference in observed species richness of skin, saliva and stool microbiota It will be analyzed if microbial communities are different between treatments Baseline, 3 month, 1 year, 2 year, 3 year
Secondary Difference in taxonomies of skin, saliva and stool microbiota It will be analyzed if microbial communities are different between treatments Baseline, 3 month, 1 year, 2 year, 3 year
Secondary Distribution of white blood cells It will be analyzed if the distribution is different between treatments Baseline, 3 month, 1 year, 2 year, 3 year
Secondary White blood cell transcriptomics White blood cell transcriptome is analyzed with single cell RNA sequencing. Baseline, 3 month, 1 year, 2 year, 3 year
Secondary Plasma cytokines Cytokines will be analyzed analyzed with Meso Scale. Baseline, 3 month, 1 year, 2 year, 3 year
Secondary Skin cytokines Cytokines will be analyzed using skin tape strip samples. Baseline, 3 month, 1 year, 2 year, 3 year
Secondary Infectious diseases Infections will be recorded with questionnaires. Baseline, 3 month, 1 year, 2 year, 3 year
Secondary Asthma symptoms Asthma symptoms will be recorded with questionnaires. Baseline, 3 month, 1 year, 2 year, 3 year
Secondary Atopic dermatitis Atopic dermatitis will be recorded with questionnaires. Baseline, 3 month, 1 year, 2 year, 3 year
Secondary Allergy Allergies will be recorded with questionnaires. Baseline, 3 month, 1 year, 2 year, 3 year
Secondary Patient-oriented Eczema Measure Lower score on patient-oriented Eczema Measure among intervention treatment compared to control that indicates lower eczema among intervention treatment. Minimum 0, maximum 28. Baseline, 3 month, 1 year, 2 year, 3 year
Secondary Wechsler Preschool and Primary Scale of Intelligence Higher score on Wechsler Preschool and Primary Scale of Intelligence among intervention treatment compared to control that indicates better cognitive skills among intervention treatment. Minimum 40, maximum 170. Baseline, 3 month, 1 year, 2 year, 3 year
See also
  Status Clinical Trial Phase
Completed NCT05018806 - Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis Phase 2
Terminated NCT03847389 - Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis Phase 1/Phase 2
Completed NCT04090229 - A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis Phase 1
Active, not recruiting NCT05388760 - Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1) Phase 2
Completed NCT05530707 - Evaluation of Acceptability, Skin Barrier Restoration and Balance of Atopic Skin Using Moisturizer N/A
Completed NCT02595073 - Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis Phase 3
Recruiting NCT05509023 - Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD) Phase 2
Recruiting NCT05048056 - Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis Phase 2
Completed NCT04598269 - Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis Phase 2
Recruiting NCT03936335 - An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
Withdrawn NCT03089476 - Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy N/A
Recruiting NCT05029895 - A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacitinib in Adolescent Participants Ages 12 to <18 Years Old Diagnosed With Atopic Dermatitis (AD)
Terminated NCT03654755 - Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis Phase 2
Completed NCT04556461 - Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier Function Phase 2
Recruiting NCT04818138 - BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort N/A
Completed NCT03719742 - A Clinical Study to Evaluate the Safety and Efficacy of a Baby Cleanser and a Moisturizer N/A
Completed NCT05375955 - A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis. Phase 2
Completed NCT03441568 - In-home Use Test of the New Modified Diprobase Formulation to Assess the Safety and Tolerability in Infants and Children Under Physician's Control N/A
Recruiting NCT06366932 - Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models Phase 4
Completed NCT03304470 - A Study to Evaluate the Safety and Efficacy of ATx201 in Subjects With Moderate Atopic Dermatitis Phase 2